Skip to main content
Healing Reimagined

Immunicom, a late-stage clinical “Immuno-Oncology” company, is focused on creating novel immunotherapies based on its breakthrough technology platform Immunopheresis™ – designed to address unmet medical needs in cancer, inflammatory, cardiovascular, renal, and autoimmune diseases.

*For Accredited Investors Only

Contact to Invest
About Us

Immunicom creates novel immunotherapies designed to treat a variety of diseases using Immunicom’s breakthrough Immunopheresis® technology platform.

  • Subtractive Adjunct Therapy that is Safe​
  • Unique Molecule Delivery
  • Optimal Adjunct IO Therapy
  • Applicable to All Cancers and other Terminal Diseases
Investor Brief
  • Reg D Offerings (Regulations Definitions)
  • Minimum Investment: $250,000
  • Company Raise: $25,000,000